Methods of providing solriamfetol therapy to subjects with impaired renal function
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
1. A method of improving wakefulness in a patient aged 65 years or over with excessive daytime sleepiness in need thereof, said method comprising:
(a) determining the renal status of the patient aged 65 years or over having excessive daytime sleepiness by measuring the estimated glomerular filtration rate (eGFR) of the patient in mL/min/1.73 m 2 as calculated by the Modification of Diet in Renal Disease equation; and
(b) providing the patient:
a first oral daily dose equivalent to 37.5 mg [R]-2-amino-3-phenylpropylcarbamate (APC),
after at least 3 days a second oral daily dose equivalent to 75 mg APC, and
after at least 3 days a third oral daily dose equivalent to 150 mg APC,
wherein the patient is not provided a daily dose exceeding a dose equivalent to 150 mg APC, when the patient has an eGFR of about 60 mL/min/1.73 m 2 to about 89 mL/min/1.73 m 2 or about 90 mL/min/1.73 m 2 or more;
(c) providing the patient:
a first oral daily dose equivalent to 37.5 mg APC from day one to day n 1 of a dose escalation regimen, and
a second oral daily dose equivalent to 75 mg APC starting on day n 2 of the dose escalation regimen,
wherein n 1 is an integer equal to or greater than 5 and n 2 is equal to the sum of n 1 +1, wherein the renally impaired subject is not provided a daily dose exceeding a dose equivalent to 75 mg APC, when the patient has an eGFR of about 30 mL/min/1.73 m 2 to about 59 mL/min/1.73 m 2 ;
(d) providing the patient:
an oral daily dose equivalent to 37.5 mg APC;
wherein the renally impaired subject is not provided a daily dose exceeding a dose equivalent to 37.5 mg APC, when the patient has an eGFR of about 15 mL/min/1.73 m 2 to about 29 mL/min/1.73 m 2 ; and
(e) when the patient has an eGFR of less than 15 mL/min/1.73 m 2 then avoiding use of APC in the patient.
2. The method of claim 1 , wherein the excessive daytime sleepiness is due to narcolepsy.
3. The method of claim 1 , wherein the excessive daytime sleepiness is due to obstructive sleep apnea.
4. The method of claim 1 , wherein the excessive daytime sleepiness is associated with shift work disorder.
5. The method of claim 1 , wherein the patient is provided said first oral daily dose or said oral daily dose in the form of about 44.7 mg APC-HCl.
6. The method of claim 1 , wherein the patient is provided said second oral daily dose in the form of about 89.3 mg APC-HCl.
7. The method of claim 1 , wherein the patient is provided said third oral daily dose in the form of about 178.5 mg APC-HCl.
8. The method of claim 1 , wherein the patient is provided said first oral daily dose in the form of about 44.7 mg APC-HCl, said second oral daily dose in the form of about 89.3 mg APC-HCl, and said third oral daily dose in the form of about 178.5 mg APC-HCl.
9. The method of claim 1 , wherein said first oral daily dose, said second oral daily dose, and said third oral daily dose are each administered upon the patient's awakening.
10. The method of claim 1 , wherein said first oral daily dose, said second oral daily dose, and said third oral daily dose are each administered more than nine hours in advance of the patient's bedtime.
11. The method of claim 1 , wherein n 1 is an integer equal to or greater than 7.
12. The method of claim 1 , wherein the excessive daytime sleepiness is due to depression.